Richard A. Gonzalez - Dec 9, 2021 Form 4 Insider Report for AbbVie Inc. (ABBV)

Role
Chairman of the Board and CEO, Director
Signature
Steven L. Scrogham, attorney-in-fact for Richard A. Gonzalez
Stock symbol
ABBV
Transactions as of
Dec 9, 2021
Transactions value $
-$21,453,641
Form type
4
Date filed
12/10/2021, 04:02 PM
Next filing
Feb 22, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABBV Common Stock, $0.01 par value Options Exercise $10.7M +174K +46.23% $61.36 551K Dec 9, 2021 Direct
transaction ABBV Common Stock, $0.01 par value Sale -$7.92M -64.5K -11.71% $122.80 486K Dec 9, 2021 Direct F1
transaction ABBV Common Stock, $0.01 par value Sale -$13.5M -110K -22.55% $123.48 377K Dec 9, 2021 Direct F2
holding ABBV Common Stock, $0.01 par value 17.6K Dec 9, 2021 By Spouse F3
holding ABBV Common Stock, $0.01 par value 5.9K Dec 9, 2021 By Step-daughter F3
holding ABBV Common Stock, $0.01 par value 5.9K Dec 9, 2021 By Step-son F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABBV Option (Right To Buy) Options Exercise -$10.7M -174K -66.67% $61.36 87.1K Dec 9, 2021 Common Stock 174K $0.00 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.19 to $123.18 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.19 to $123.48 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The reporting person disclaims beneficial ownership of these securities.
F4 Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

Remarks:

The option exercise and sale transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).